Pfizer’s flibanserin, marketed as Addyi, is currently the only FDA-approved medication specifically for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It’s crucial to understand that Addyi isn’t a “women’s Viagra.” It works differently.
Unlike Viagra, which addresses erectile dysfunction by increasing blood flow, Addyi targets brain chemistry. It affects serotonin, dopamine, and norepinephrine levels, believed to play a role in sexual desire.
- Mechanism of Action: Addyi modulates neurotransmitter activity, potentially increasing sexual desire. Prescription Requirements: A doctor’s prescription is mandatory. Patients undergo a thorough evaluation to rule out other underlying medical conditions contributing to low libido. Side Effects: Common side effects include dizziness, nausea, sleepiness, and low blood pressure. Serious interactions with alcohol are possible; alcohol consumption is strictly prohibited during treatment. Effectiveness: Studies show a modest increase in sexual desire in some women, but results vary significantly. It’s not effective for all women. Dosage: Typically, a daily dose is prescribed at bedtime.
Before starting Addyi:
Discuss all medications, supplements, and health conditions with your doctor. Understand potential side effects and contraindications. Explore other potential causes of low libido with your healthcare provider. Realistically assess your expectations; Addyi may not be a solution for everyone.
Remember, Addyi’s effectiveness depends on individual factors and adherence to prescribed guidelines. Consult your physician for personalized advice and to determine if Addyi is right for you. Other treatments for HSDD exist, so a range of options should be considered.
